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ORIGINAL ARTICLE
Exhaled nitric oxide levels in patients with atopic cough and cough
variant asthma
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Exhaled nitric oxide levels in patients with atopic cough and cough variant asthma
FUJIMURA M, OHKURA N, ABO M, FURUSHO S, WASEDA Y, ICHIKAWA Y, HARA J. Respirology 2008;
••: ••–••
Background and objective: Atopic cough (AC) is an established clinical entity in Japan, in which
patients present with a chronic persistent non-productive cough. Exhaled nitric oxide (NO) is a
biomarker of eosinophilic airway inflammation. The present study examined whether exhaled NO
levels were increased in AC in comparison with cough variant asthma (CVA) and bronchial asthma
(BA).
Methods: Consecutive patients presenting with an isolated cough lasting at least 8 weeks were
enrolled in the study. The aetiology of the chronic cough was determined according to the Japanese
Respiratory Society guidelines for management of cough. Exhaled NO, capsaicin cough sensitivity
(C5) and bronchial reversibility were measured at the patients’ first visit. Bronchial responsiveness
(PC20 to methacholine) was measured at their second visit following a 6-day course of broncho-
dilator therapy.
Results: There were 58 patients recruited and fully investigated; of these 9 and 11 patients were
diagnosed with AC and CVA, respectively, as single causes of chronic cough. Ten patients with BA who
had not received corticosteroid therapy in the previous 4 weeks and who attended the same clinic in
the same time period acted as controls. Exhaled NO levels in patients with AC were significantly lower
than those in patients with CVA and BA. There was no significant difference in the exhaled NO levels
between patients with CVA and BA.
Conclusions: Exhaled NO may reflect eosinophilic inflammation of peripheral airways and its
measurement may be useful in differentiating CVA from AC and other causes of chronic non-
productive cough.
Key words: atopic cough, bronchial asthma, cough variant asthma, exhaled nitric oxide, non-
asthmatic eosinophilic bronchitis.
INTRODUCTION
Cough variant asthma (CVA) and atopic cough (AC)
are major causes of chronic non-productive cough.1
AC is a new clinical entity in Japan, in which patients
present with a bronchodilator-resistant non-
productive cough.2 Bronchodilator therapy has
antitussive efficacy only in CVA. The fundamental fea-
tures of AC include eosinophilic inflammation of the
central airways and increased cough reflex sensitiv-
ity,3 while those of CVA are eosinophilic inflammation
of the central to peripheral airways4 and mildly
increased bronchial responsiveness.5 CVA is recog-
nized as a precursor of asthma, which develops in
nearly 30% of patients with CVA.6,7 AC is not a precur-
sor of asthma.7
Exhaled nitric oxide (NO) levels are an index of
eosinophilic airway inflammation.8 De Diego et al.
reported that exhaled NO levels were similar in CVA
and bronchial asthma (BA) patients;9 however,
exhaled NO levels have not been reported in AC
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patients. The present study was conducted to eluci-
date whether exhaled NO levels are increased in AC in
comparison with CVA and BA.
METHODS
Study design
A cross-sectional observational study was used to
compare patients with AC, CVA and BA. Consecutive
patients presenting in the 2-year period from October
2004 to September 2006, with an isolated cough
lasting at least 8 weeks, were enrolled. At the first
clinic visit, patients underwent the following
sequence of tests: measurement of exhaled NO con-
centration, capsaicin cough sensitivity and bronchial
reversibility, sputum induction by inhalation of 5%
saline solution, and assessment of atopic characteris-
tics. Each patient then received bronchodilator
therapy (oral clenbuterol, 40 mg/day + inhaled salb-
utamol sulphate, 200 mg, on demand) for 6 days until
the day before the second clinic visit. At the second
clinic visit, efficacy of the bronchodilator therapy on
cough was assessed as described below and bronchial
responsiveness to methacholine was measured. Each
patient then received appropriate treatment accord-
ing to the Japanese Respiratory Society (JRS) guide-
lines for the management of cough.2 The study
protocol was approved by the ethics committee of the
Kanazawa University Hospital and all participants
gave informed consent.
Control values for exhaled levels of NO were deter-
mined as the levels measured in patients with BA,
who also attended the clinic during the period of
study recruitment and had not been treated with
inhaled or systemic corticosteroids during the previ-
ous 4 weeks. The diagnosis of BA was based on the
following three criteria: (i) a history of recurrent epi-
sodes of wheezing; (ii) reversible airway obstruction
documented by a physician; and (iii) an improvement
of 12% or more and 200 mL or more in FEV1 after
inhalation of 300 mg of salbutamol sulphate.
Assessment of efficacy of treatment on cough
Efficacy of the treatment on cough was assessed using
a visual analogue scale from 0 to 10 cm. At each clinic
visit, each patient was asked to indicate which point
on the scale represented their current cough experi-
ence. Response to bronchodilator therapy, which is
the most important criterion for the diagnosis of CVA,
was judged to be effective when the point on the
visual analogue scale at the second visit, after 6-day
therapy with bronchodilator, was 7 cm or less.
Diagnosis of AC and CVA
Atopic cough and CVA as sole causes of chronic cough
were diagnosed according to the following criteria for
the selection of subjects in clinical studies, as recom-
mended by JRS.2 Patients with a probable diagnosis of
AC or CVA, based on the brief JRS diagnostic criteria,2
were excluded from this study.
The diagnosis of AC was made according to the
following criteria:2
• Non-productive cough lasting more than 8 weeks
without wheezing or dyspnoea
• Presence of one or more findings indicative of an
atopic constitution, including a past history and/or
complications of allergic diseases excluding asthma,
peripheral blood eosinophilia (>5% or >400 cells/mL),
elevated total serum IgE (>150 IU/mL), positive spe-
cific IgE antibody to aeroallergens and/or induced
sputum eosinophilia (2.5%)
• No bronchial reversibility, defined as less than
a 10% increase in FEV1 after inhalation of 300 mg of
salbutamol sulphate
• Bronchial responsiveness within normal limits
(PC20  10 mg/mL)
• Increased cough reflex sensitivity (capsaicin
concentration eliciting five or more coughs
(C5)  3.9 mM)
• Cough resistant to bronchodilator therapy (oral
clenbuterol 40 mg/day plus inhaled salbutamol 200 mg
at bedtime and on demand)
• No abnormal findings indicative of cough aetiology
on CXR
• Normal FEV1 (80% of predicted value), FVC (80%
of predicted value) and FEV1/FVC ratio (70%)
When all criteria were satisfied, a definite diagnosis of
AC was applied. All patients diagnosed with AC were
successfully treated with histamine H1-antagonists
alone and/or with inhaled and/or oral corticosteroids.
The diagnosis of CVA was made according to the
following criteria:2
• Isolated chronic non-productive cough lasting
more than 8 weeks
• Absence of a history of wheezing or dyspnoea, and
no adventitious lung sounds on physical examination
• Absence of postnasal drip accounting for the cough
• FEV1, FVC and FEV1/FVC ratio within normal limits
• Presence of BHR (PC20 < 10 mg/mL)
• Relief of cough with bronchodilator therapy
• No abnormal findings indicative of cough aetiology
on CXR
When all criteria were satisfied, a definite diagnosis
of CVA was applied. All patients with CVA had been
successfully treated with bronchodilators, the
leukotriene antagonist, montelukast and/or inhaled
corticosteroids.
Measurement of exhaled NO concentration
Exhaled NO concentrations were measured by the
online method using a chemiluminescence analyser
(model 280, Sievers Instruments, Boulder, CO, USA)
according to the American Thoracic Society (ATS)
guidelines,10 between 9 am and 1 pm at the patient’s
first visit. Expiratory flow rate was 0.05 L/s as recom-
mended by the guidelines and exhalation pressure
was 16 cm H2O. Measurement of exhaled NO was
repeated until three reproducible NO plateau values
were achieved. Exhaled NO was then calculated as the
M Fujimura et al.2
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mean of these three values and exhaled NO values in
10 patients with BA were used as control values.
Pulmonary function testing
Routine pulmonary function, cough reflex sensitivity
and bronchial reversibility were measured in that
order at the first visit, and bronchial responsiveness
was determined at the second visit, 1 week after the
first visit. FVC, FEV1 and flow–volume curves were
measured using a dry wedge spirometer (Chestac 11,
Chest Co. Ltd, Tokyo, Japan). Spirometry was per-
formed and evaluated according to the ATS criteria.11
Capsaicin cough threshold (C5) was measured as an
index of cough reflex sensitivity.12,13 To assess bron-
chial reversibility, spirometry was performed before
and 30 min after inhalation of 300 mg of salbutamol
sulphate. The provocative concentration of metha-
choline causing a 20% fall in FEV1 from pre-challenge
values (PC20) was measured as an index of non-
specific bronchial responsiveness.14
Statistical analysis
Data values for exhaled NO, capsaicin cough thresh-
old (C5) and bronchial responsiveness (PC20) were
expressed as geometric mean with geometric stan-
dard error of the mean (GSEM). Other data values
were expressed as mean and SD. Differences in data
values between patients with AC, CVA and BA were
analysed by one-way analysis of variance (anova) fol-
lowed by Fisher’s partial least squares difference. Data
for exhaled NO, PC20 and C5 were logarithmically
transformed. P-values < 0.05 were considered statisti-
cally significant.
RESULTS
The diagnostic procedures were completed in 58 of
the 80 patients with chronic cough who were enrolled
in the study. Of the 58 patients, 9 and 11 patients,
respectively, met the diagnostic criteria for AC and
CVA as the sole causes of chronic cough. Patient char-
acteristics are summarized in Table 1. Duration of
cough before the initial visit, successful treatment for
relief of cough and time required after the first visit for
relief of cough are summarized for individual patients
with AC and CVA in Table 2. The atopic characteristics
of patients with AC and CVA are shown in Table 3.
Exhaled NO levels in patients with AC (13.0 p.p.b.,
GSEM 1.14) were significantly lower than those
in patients with CVA (39.4 p.p.b., GSEM 1.25,
P = 0.0007) or BA (36.1 p.p.b., GSEM 1.26, P = 0.0020)
(Fig. 1). There was no significant difference in the
exhaled NO levels between patients with CVA and BA
(P = 0.7618).
Table 1 Characteristics of patients with atopic cough (AC), cough variant asthma (CVA) and typical bronchial asthma (BA)
AC CVA BA
Number of subjects 9 11 10
Gender (male : female) 2:7 2:9 3:7
Age (years) 42.8  13.1 44.8  16.1 43.0  18.9
Height (cm) 164.3  7.1 160.0  8.8 157.9  5.2
Body weight (kg) 62.7  13.1 55.7  8.4 55.1  10.8
FVC, % predicted 119.2  9.0 111.3  19.6 102.4  14.2
FEV1, % predicted 103.3  10.1 98.1  10.7 83.6  12.5***$$
FEV1/FVC (%) 80.1  7.6 79.4  9.9 72.1  13.6
C5 (mM) 1.0 (1.20) 18.9 (1.4)**** 7.8 (2.2)**
PC20 (mg/mL) 39.7 (1.52) 2.4 (1.22)**** 0.81 (1.60)****$
**P < 0.01, ***P < 0.001 and ****P < 0.0001 compared with AC; $P < 0.05 and $$P < 0.01 compared with CVA.
Data are presented as mean  SD. Data in C5 are presented as geometric mean (geometric standard error of the mean).

























Figure 1 Exhaled nitric oxide (NO) levels in patients with
atopic cough, cough variant asthma and typical bronchial
asthma. Horizontal bars represent geometric mean values.
P-values as determined by Fisher’s partial least squares
difference are shown.
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Table 2 Results of treatment in patients with atopic cough (AC) and cough variant asthma (CVA)
Patient Age (years) Sex
Symptom duration
(months) Successful treatment
Time† for relief of
cough (weeks)
AC
1 52 F 8 Azelastine, FP, PSL 9
2 39 F 2 Azelastine 4
3 63 F 2 Azelastine 4
4 41 F 7 Azelastine, FP 5
5 21 M 2 FP, PSL 10
6 40 F 2 Azelastine 4
7 51 F 2 Azelastine, FP 4
8 51 M 24 Azelastine, FP 6
9 27 F 2 Azelastine 3
CVA
1 37 F 4 Clenbuterol 1
2 41 F 2 Clenbuterol 8
3 52 F 2 Clenbuterol, montelukast 4
4 69 F 120 Procaterol, theophylline 3
5 46 F 4 Clenbuterol, salbutamol inhaled 4
6 17 F 2 Clenbuterol 6
7 30 F 5 Clenbuterol, montelukast, salmeterol inhaled 2
8 55 M 3 BDP 4
9 64 M 2 Clenbuterol, BUD, salmeterol inhaled 4
10 27 F 3 Montelukast, BUD 5
11 55 F 5 Clenbuterol, montelukast, BUD 8
†Time required to relive cough after the first visit.
BDP, beclomethasone dipropionate inhalation (200–400 mg bd); BUD, budesonide inhalation (200–400 mg bd); F, female; FP,
fluticasone dipropionate inhalation (200–400 mg bd); M, male; PSL, oral prednisolone (20 mg once daily) for less than 3 weeks.















1 — — — 7.6 251 NG 11 —
2 — — — 1.0 42 0 32 JC
3 PO UR — 3.7 218 0 138 —
4 UR — — 0.7 43 NG 94 —
5 CBA PO — 3.7 283 NG 2200 HD, D, RW, JC
6 — — AR 2.0 138 NG 220 HD
7 — — — 3.3 158 NG 68 RW, JC
8 — UR — 4.0 176 NG 86 HD, D
9 — PO, AD — 8.2 558 19.5 175 JC, HD, D, CD
CVA
1 UR — — 1.5 72 0 40 —
2 — — — 3.0 255 NG 0 —
3 — — — 1.0 63 NG 56 HD, RW
4 — — — 1.5 60 NG 58 —
5 — AR — 0 0 1.0 9 —
6 — AR BA 3.0 177 NG 0 —
7 — — — 6.0 360 NG 320 HD, D
8 — — — 10.8 756 3.6 187 JC, RW
9 AR, UR — — 1.0 69 NG 32 —
10 CBA PO AR 4.8 262 0.8 504 HD, D
11 — — — 1.9 110 NG 61 JC
†Per cent of nucleated cells.
AD, atopic dermatitis; AR, allergic rhinitis; BA, bronchial asthma; CBA, ••; CD, cat dander; D, Dermatophagoides; HD, house
dust; JC, Japanese cedar; NG, inadequate sputum sample; PO, pollinsis; RW, ragweed; UR, urticaria.
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DISCUSSION
The present study showed that exhaled NO levels
were significantly lower in patients with AC compared
with patients with CVA or BA. Normal values of
exhaled NO could not be determined in this study
because it was difficult to recruit gender- and age-
matched, non-atopic, never-smoking normal sub-
jects. Exhaled NO is a biomarker of eosinophilic
airway inflammation, which is increased in steroid-
naive asthmatic patients.8 Two diagnostic criteria for
each cause of chronic cough are recommended by the
JRS.2 One set of criteria is for the selection of subjects
for clinical studies (research use) and the second set
comprises brief criteria for clinical use. In the present
study, only patients with AC and CVA, diagnosed
according to the criteria for research use,2 were
included. The more strict diagnostic criteria for
research use are applied to standardize the selection
of subjects for clinical studies so that data are avail-
able to all research groups. It is difficult to satisfy all
the required criteria for research use, which accounts
for the small proportion of enrolled patients who
actually completed the present study. Further studies
using the brief diagnostic criteria for AC and CVA may
be of value in assessing whether measurement of
exhaled NO is useful for making the diagnosis of CVA
in clinical practice.
Chronic cough is defined as isolated persistent
cough lasting 8 weeks. CVA is strictly diagnosed
when a patient with an isolated chronic cough, who
has no history of wheezing or dyspnoea indicative of
BA and no wheezes on lung auscultation, responds to
bronchodilator therapy.5 Although non-specific bron-
chial responsiveness is mildly increased in this group
of patients,5,7 there is considerable overlap with
normal subjects.15 In addition, Irwin and coworkers
have shown that measurement of bronchial respon-
siveness cannot predict the efficacy of bronchodilator
therapy in patients with isolated chronic cough.16
Efficacy of bronchodilator therapy in preventing
cough is the most important criterion for the diagno-
sis of CVA, and increased bronchial responsiveness is
the second. This is however disputed by some chest
physicians who believe that chronic cough with
increased bronchial responsiveness is CVA. Therefore
in the present study, patients with CVA were selected
only if their cough responded to bronchodilator
therapy and bronchial responsiveness was increased.
Atopic cough is a recently described clinical entity
in Japan, in which patients present with a chronic
isolated bronchodilator-resistant non-productive
cough.2 The fundamental features are increased
cough reflex sensitivity,3,7,15 with normal bronchial
responsiveness and eosinophilic inflammation of
central airways.3 These features differ from those of
CVA: increased bronchial responsiveness5,15 and
eosinophilic inflammation of central to peripheral
airways.4 CVA is a precursor of typical asthma but AC
is not.7
In many countries non-asthmatic eosinophilic
bronchitis (EB) is being accepted as a clinical entity in
patients presenting with chronic cough that responds
to corticosteroid therapy.17 The diagnostic criteria are
sputum eosinophilia and normal bronchial respon-
siveness.17 It has been reported that in such patients
with EB, cough reflex sensitivity is increased,18 eosi-
nophils in BAL fluid are increased19,20 and onset of
asthma is typical.21 Two studies have shown that
exhaled NO levels in patients with EB are increased to
the same levels as those in patients with BA.20,22 It
appears that there are differences between AC and EB
(Table 4) and that AC is different from EB. The find-
ings that exhaled NO and eosinophils in BAL fluid are
increased in BA and EB, but not in AC, suggest that
exhaled NO reflects eosinophilic inflammation of
peripheral airways, which have a much larger surface
area than the central airways.
Table 4 Comparison between atopic cough, non-asthmatic eosinophilic bronchitis and cough variant asthma




Cough reflex sensitivity Not increased Normal Increased
Bronchial responsiveness Increased but less than asthma Not increased Not increased
Pathology
Eosinophils in
Induced sputum Increased Increased Increased
Biopsied bronchi Increased same as asthma Increased but less than asthma Increased same as asthma
BAL fluid Increased same as asthma Not increased Increased same as asthma†
Inflammatory markers
Exhaled NO Increased No increased Increased
Outcome
Asthma onset without ICS 30% No Not investigated
with ICS 6% Not investigated 9%
†Asthmatics treated with inhaled corticosteroids.
Underlined findings were from the present study.
ICS, ••; NO, nitric oxide.
Exhaled NO in atopic cough 5
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De Diego et al. compared airway inflammatory
markers in patients with typical asthma and those
with CVA, which was diagnosed by both increased
bronchial responsiveness and relief of cough with
bronchodilator therapy, as in the present study.9 The
authors showed that there was no difference in
exhaled NO, cough reflex sensitivity or bronchial
responsiveness in typical asthma compared with CVA.
Similar levels of exhaled NO and cough reflex sensi-
tivity were confirmed in the present study, while
bronchial responsiveness was increased in typical
asthma compared with CVA. It is likely that typical
asthma was more severe in the present study com-
pared with the study of De Diego and coworkers.
Based on this, it is concluded that exhaled NO levels
are increased in CVA to the same levels seen in
steroid-naive typical asthma.
In conclusion, this study confirmed that the patho-
genesis of AC is different from that of CVA or EB, and
suggests that exhaled NO may reflect eosinophilic
inflammation of peripheral airways. The lower levels
of exhaled NO in AC may be useful in differentiating
it from CVA, EB and other causes of chronic non-
productive cough.23
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During the preparation of your manuscript, the questions listed below have arisen. Please answer all the




q1 Author: Should ‘C5’ be defined here as ‘capsaicin concentration eliciting five
or more coughs (C5)’?
q2 Author: ‘Capsaicin cough threshold (C5), the concentration of capsaicin
solution eliciting five or more coughs, was measured as an index of cough
reflex sensitivity’ has been changed to ‘Capsaicin cough threshold (C5) was
measured as an index of cough reflex sensitivity’. Is this OK? (‘C5’ has been
defined earlier)
q3 Author: Can ‘provocative concentration of methacholine causing a 20% fall in
FEV1 from pre-challenge values (PC20)’ be simplified as ‘PC20’? (According
to the journal style, ‘PC20’ is not necessary to be defined)
q4 Author: Should ‘Data in C5’ be changed to ‘Data in C5 and PC20’?
q5 Author: ‘C5’ has been defined as ‘capsaicin concentration eliciting five or more
coughs’. Is this OK?
q6 Author: Please define: CBA
q7 Author: Can ‘Dermatophagoides’ be changed to ‘dermatophagoides’?
q8 Author: What do the italics and boldface indicate?
q9 Author: Please define: ICS
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